BCL2L1 and atherosclerosis: There were six targets in the intersection with 137 candidate therapeutic targets of XFZYD, which included upregulated PTGS2, MMP9, and BCL2L1 and downregulated JUN, VEGFA, and CXCL2 in the atherosclerosis group (Table 2).